FDA Approves Enhertu-Perjeta Combo for First-Line Treatment of HER2+ Metastatic Breast Cancer
The FDA approved the combination of Enhertu (fam-trastuzumab deruxtecan-nxki, or T-DXd) and Perjeta (pertuzumab) for first-line treatment of unresectable or metastatic HER2-positive breast cancer.23
Approval is based on results from a phase 3 clinical trial.3
This marks Enhertu's expansion into first-line use for this indication.4
Sources:
2. http://nursing.onclive.com/view/enhertu-perjeta-combo-earns-fda-approval-in-advanced-her2-breast-cancer
3. https://www.onclive.com/view/fda-approves-t-dxd-plus-pertuzumab-for-her2-breast-cancer